2026-04-17T09:45:13Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1116422025-12-05T13:08:53Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study Gómez Acebo, Inés Dierssen Sotos, Trinidad Palazuelos-Calderón, Camilo Pérez Gómez, Beatriz Lope, Virginia Tusquets, Ignasi Alonso Aguado, Maria Henar Moreno Aguado, Víctor Amiano, Pilar Molina de la Torre, Antonio José Barricarte, Aurelio Tardón, Adonina Camacho, Antonio Peiró Pérez, Rosana Marcos Gragera, Rafael Muñoz, Montse Michelena Echeveste, Maria Jesús Ortega Valin, Luis Guevara, Marcela Castaño-Vinyals, Gemma Aragonès Sanz, Núria Kogevinas, Manolis Pollán, Marina Llorca Díaz, Javier Càncer de mama Hormones Hormonoteràpia Oncologia Canals de calci Breast cancer Hormones Hormone therapy Oncology Calcium channels INTRODUCTION: The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. METHODS: In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. RESULTS: The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. CONCLUSIONS: In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women). 2017-05-29T08:20:41Z 2017-05-29T08:20:41Z 2016-08-10 2017-05-29T08:20:41Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0159672 PLoS One, 2016, vol. 11, num. 8, p. e0159672 https://doi.org/10.1371/journal.pone.0159672 cc-by (c) Gómez-Acebo, Ines et al., 2016 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess Public Library of Science (PLoS) Articles publicats en revistes (Ciències Clíniques)